Radioactive Beams in Particle Therapy: Past, Present, and Future

Durante, Marco; Parodi, Katia

doi:10.3389/fphy.2020.00326

Cited by 35 publications

(31 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Feasibility of radioactive ion beams 10,11 C, 13 N, 14,15 O, 17,18 F and 18,19 Ne was investigated [50,[94][95][96] and reviewed [97] for inbeam positron emission tomography imaging in ion therapy. In the case of 11 C and 15 O, the difference in the Bragg peak position and the position of the maximum positron emitting fragments was negligible for ideal monoenergetic beams, but this difference increased with and was strongly influenced by the energy spread of the primary beams [94].…”

Section: Theranostics Using Radioactive Isotopesmentioning

confidence: 99%

Secondary Radiation in Ion Therapy and Theranostics: A Review

Nandy

2021

Front. Phys.

View full text Add to dashboard Cite

Ion therapy has emerged as one of the preferred treatment procedures in some selective indication of cancer. The actual dose delivered to the target volume may differ from the planned dose due to wrong positioning of the patient and organ movement during beam delivery. On the other hand, some healthy tissues outside the planned volume may be exposed to radiation dose. It is necessary to determine the primary particle range and the actual exposed volume during irradiation. Many proposed techniques use secondary radiation for the purpose. The secondary radiation consists mainly of neutrons, charged fragments, annihilation photons, among others, and prompt gammas. These are produced through nuclear interaction of the primary beam with the beam line and the patient’s body tissue. Besides its usefulness in characterizing the primary beam, the secondary radiation contributes to the risk of exposure of different tissues. Secondary radiation has significant contribution in theranostics, a comparatively new branch of medicine, which combines diagnosis and therapy. Many authors have made detailed study of the dose delivered to the patient by the secondary radiation and its effects. They have also studied the correlation of secondary charged particles with the beam range and the delivered dose. While these studies have been carried out in great detail in the case of proton and carbon therapy, there are fewer analyses for theranostics. In the present review, a brief account of the studies carried out so far on secondary radiation in ion therapy, its effect, and the role of nuclear reactions is given.

show abstract

Section: Theranostics Using Radioactive Isotopesmentioning

confidence: 99%

Secondary Radiation in Ion Therapy and Theranostics: A Review

Nandy

2021

Front. Phys.

View full text Add to dashboard Cite

show abstract

“…A wide range of radioisotopes can be produced by CERN-Medicis, including positron, alpha, Auger, and conversion electron emitters ( 10 ). Various chemical species, such as lanthanides, halogens, transition metals, and alkaline earth metals are available.…”

Section: General Applicationsmentioning

confidence: 99%

New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review

et al. 2021

View full text Add to dashboard Cite

The use of radioactivity in medicine has been developed over a century. The discovery of radioisotopes and their interactions with living cells and tissue has led to the emergence of new diagnostic and therapeutic modalities. The CERN-MEDICIS infrastructure, recently inaugurated at the European Center for Nuclear Research (CERN), provides a wide range of radioisotopes of interest for diagnosis and treatment in oncology. Our objective is to draw attention to the progress made in nuclear medicine in collaboration with CERN and potential future applications, in particular for the treatment of aggressive tumors such as pancreatic adenocarcinoma, through an extensive review of literature. Fifty seven out of two hundred and ten articles, published between 1997 and 2020, were selected based on relevancy. Meetings were held with a multi-disciplinary team, including specialists in physics, biological engineering, chemistry, oncology and surgery, all actively involved in the CERN-MEDICIS project. In summary, new diagnostic, and therapeutic modalities are emerging for the treatment of pancreatic adenocarcinoma. Targeted radiotherapy or brachytherapy could be combined with existing therapies to improve the quality of life and survival of these patients. Many studies are still in the pre-clinical stage but open new paths for patients with poor prognosis.

show abstract

“…Research at FAIR will therefore continue in these directions, according to the new opportunities that the SIS100 energies and the upgraded intensities offer (Figure 1). The new research programs include the construction of a galactic cosmic ray simulator [43], highenergy particle radiography [44], FLASH irradiations with heavy ions [45], and testing of carbon and oxygen radioactive isotopes for therapy and simultaneous imaging by PET [36], a program that has been supported by a recent ERC Advanced Grant (BARB) 3 . The Biophysics Department will benefit from FAIR with a new experimental vault, the APPA cave (Figure 3), where especially high-energy space radiation protection experiments will be performed.…”

Section: Biomedical Research Programs At Particle Accelerators Fairmentioning

confidence: 99%

“…High intensity is also useful for spatially fractionated radiotherapy using protons [30] or heavier ions [31], a method that largely reduces normal tissue toxicity in animal models [32][33][34]. Finally, radioactive ion beams (RIB), one of the main nuclear physics topics that justify the construction of new nuclear physics facilities [35], are potentially an extraordinary tool for therapy as they allow the online visualization of beams during irradiation [36].…”

Section: Introductionmentioning

confidence: 99%

Biomedical Research Programs at Present and Future High-Energy Particle Accelerators

et al. 2020

Self Cite

View full text Add to dashboard Cite

Biomedical applications at high-energy particle accelerators have always been an important section of the applied nuclear physics research. Several new facilities are now under constructions or undergoing major upgrades. While the main goal of these facilities is often basic research in nuclear physics, they acknowledge the importance of including biomedical research programs and of interacting with other medical accelerator facilities providing patient treatments. To harmonize the programs, avoid duplications, and foster collaboration and synergism, the International Biophysics Collaboration is providing a platform to several accelerator centers with interest in biomedical research. In this paper, we summarize the programs of various facilities in the running, upgrade, or construction phase.

show abstract

Radioactive Beams in Particle Therapy: Past, Present, and Future

Cited by 35 publications

References 98 publications

Secondary Radiation in Ion Therapy and Theranostics: A Review

Secondary Radiation in Ion Therapy and Theranostics: A Review

New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review

Biomedical Research Programs at Present and Future High-Energy Particle Accelerators

Contact Info

Product

Resources

About